成都四面体药物研究有限公司

Chengdu Tetrahedron Drug Research is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule drugs for oncology and other unmet medical needs. Headquartered in Chengdu, China, the company utilizes a proprietary structure-based drug design platform to develop highly selective inhibitors against validated but difficult-to-drug targets. Its lead candidate, TDR-0515, is a potent USP1 inhibitor currently undergoing Phase 1 clinical trials for advanced solid tumors, including ovarian and breast cancers. The company also operates as a high-end contract research organization (CRO), providing medicinal chemistry and custom synthesis services to the global pharmaceutical industry. With a team led by experienced drug hunters, Tetrahedron aims to deliver innovative therapies through efficient R&D processes.